QC
NTLA icon

Quadrature Capital’s Intellia Therapeutics NTLA Stock Holding History

Quadrature Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Sell
61,204
-13,828
-18% -$194K 0.01% 726
2026
Q1 		$962K Sell
75,032
-141,009
-65% -$1.8M 0.01% 574
2025
Q4 		$1.94M Buy
+216,041
New +$2.97M 0.02% 375
2025
Q3 		– Sell
-17,649
Closed -$165K – 1346
2025
Q2 		$165K Sell
17,649
-36,357
-67% -$299K ﹤0.01% 840
2025
Q1 		$383K Buy
+54,006
New +$545K 0.01% 655

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Quadrature Capital's NTLA Position: Q2 2026 in Review

Quadrature Capital reduced its Intellia Therapeutics (NTLA) stake by 18% in Q2 2026, selling an estimated $194K and leaving 61,204 shares worth $1.04M. The position accounts for 0.01% of the portfolio, ranked #726.

Quadrature Capital first reported a position in NTLA in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.94M in Q4 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Quadrature Capital held 61,204 shares of Intellia Therapeutics worth $1.04M as of Q2 2026.
  • Quadrature Capital sold 13,828 Intellia Therapeutics shares in Q2 2026, an estimated $194K.
  • Intellia Therapeutics made up 0.01% of Quadrature Capital's portfolio in Q2 2026, its #726 holding.
  • Quadrature Capital first reported a position in Intellia Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Quadrature Capital's Intellia Therapeutics position peaked at $1.94M in Q4 2025.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.